Cyclerion Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cyclerion Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Cyclerion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$1.32M, a 68.4% increase year-over-year.
  • Cyclerion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was $3.01M.
  • Cyclerion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$5.26M, a 88.1% increase from 2022.
  • Cyclerion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$44.1M, a 14.7% increase from 2021.
  • Cyclerion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$51.6M, a 33.6% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$5.26M +$38.8M +88.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 -$44.1M +$7.57M +14.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$51.6M +$26.2M +33.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 -$77.8M +$45.2M +36.8% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-24
2019 -$123M -$7.76M -6.73% Jan 1, 2019 Dec 31, 2019 10-K 2021-02-25
2018 -$115M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.